Role of TXA in Patients Undergoing Breast Free Flap Reconstruction

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

May 13, 2025

Study Completion Date

May 13, 2026

Conditions
Breast CancerBlood Loss, Surgical
Interventions
DRUG

Tranexamic acid

Experimental group will receive TXA intraoperatively (15mg/kg IV, once at beginning of case then re dose at 4hrs if operation goes longer) at the time of their surgery.

DRUG

Placebo

Control group will receive same volume equivalent of saline intravenously at the time of their surgery.

Trial Locations (1)

22902

RECRUITING

University of Virginia Medical Center, Charlottesville

All Listed Sponsors
lead

University of Virginia

OTHER